| Patient | Gwen Ifill |
|---|---|
| Date of birth | 1955-09-29 |
| Identifiers | MRN HR-ML032-SYN-TD; SSN (made up) 000-32-5814 |
| Document date | 2016-04-28 |
| Author | Lorna Achebe-Price, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Review at the midpoint of combination treatment, on the day of cycle 4. [S]
Ms. Ifill returns on the day of her fourth cycle. Cycles 2 and 3 were given on schedule in the infusion center. Nausea lasts a day or two after each cycle and is controlled with ondansetron two or three times. For about two weeks she has had tingling in her toes that does not affect walking or balance. Her hair has thinned and she wears a wig. She has had no diarrhea, rash, cough, breathlessness or headache. She is tired for two or three days after each cycle and works from home on those days. She has had no thoughts of self-harm. [S]
| Element | Detail |
|---|---|
| Treatment | Cycle 4 of 6 today; cycles 2 and 3 on schedule |
| Nausea | One or two days after each cycle; controlled |
| Neuropathy | Tingling in the toes for two weeks; no effect on function |
| Immune-related symptoms | None |
| Mood | PHQ-9 5 |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired for two or three days after each cycle; no fever |
| Gastrointestinal | Positive | Nausea for one or two days after each cycle; no vomiting or diarrhea |
| Neurological | Positive | Tingling in the toes; no weakness or falls; no headache |
| Integumentary | Positive | Hair thinning; no rash or itching |
| Respiratory | Negative | No cough or breathlessness |
| Endocrine | Negative | No heat or cold intolerance; no thirst |
| Psychiatric | Negative | Mood steady; no thoughts of self-harm |
7 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for pain after surgery, no more than 3 g a day | Two tablets every 6 hours as needed | Oral route | 2016-02-03 to 2016-02-17 | completed | S |
| Dostarlimab 50 mg/mL injection, 500 mg intravenously over 30 minutes on day 1 of each 21-day cycle, before carboplatin and paclitaxel, for six cycles | Day 1 every 21 days for six cycles | Intravenous route | 2016-02-24 to 2016-06-09 | completed | S |
| Carboplatin 10 mg/mL injection, 575 mg (AUC 5) intravenously on day 1 of each 21-day cycle, for six cycles | Day 1 every 21 days for six cycles | Intravenous route | 2016-02-24 to 2016-06-09 | completed | S |
| Paclitaxel 6 mg/mL injection, 320 mg (175 mg/m2) intravenously over 3 hours on day 1 of each 21-day cycle, for six cycles, after dexamethasone, diphenhydramine and famotidine | Day 1 every 21 days for six cycles | Intravenous route | 2016-02-24 to 2016-06-09 | completed | S |
| Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nausea | One tablet every 8 hours as needed for nausea | Oral route | 2016-02-24 to 2016-06-30 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2016-04-28 | Body height | 165 | cm | S |
| 2016-04-28 | Body weight | 71.8 | kg | S |
| 2016-04-28 | Body mass index (BMI) [Ratio] | 26.4 | kg/m2 | S |
| 2016-04-28 | Systolic blood pressure | 120 | mm[Hg] | S |
| 2016-04-28 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2016-04-28 | Heart rate | 82 | /min | S |
| 2016-04-28 | Respiratory rate | 16 | /min | S |
| 2016-04-28 | Body temperature | 36.6 | Cel | S |
| 2016-04-28 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2016-04-28 | Hemoglobin [Mass/volume] in Blood | 10.6 | g/dL | 12-15.5 g/dL | Low | S |
| 2016-04-28 | Leukocytes [#/volume] in Blood by Automated count | 4.3 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2016-04-28 | Neutrophils [#/volume] in Blood by Automated count | 2.1 | 10*3/uL | 1.5-7.7 10*3/uL | Normal | S |
| 2016-04-28 | Platelets [#/volume] in Blood by Automated count | 196 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2016-04-28 | Creatinine [Mass/volume] in Serum or Plasma | 0.81 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2016-04-28 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2011)/1.73 sq M | 83 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2016-04-28 | Glucose [Mass/volume] in Serum or Plasma | 97 | mg/dL | 70-99 mg/dL | Normal | S |
| 2016-04-28 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 | U/L | 7-35 U/L | Normal | S |
| 2016-04-28 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 26 | U/L | 8-35 U/L | Normal | S |
| 2016-04-28 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.5 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2016-04-28 | Magnesium [Mass/volume] in Serum or Plasma | 1.8 | mg/dL | 1.7-2.2 mg/dL | Normal | S |
| 2016-04-28 | Thyrotropin [Units/volume] in Serum or Plasma | 4.8 | m[IU]/L | 0.4-4.5 mIU/L | High | S |
| 2016-04-28 | Thyroxine (T4) free [Mass/volume] in Serum or Plasma | 1.1 | ng/dL | 0.8-1.8 ng/dL | Normal | S |
| 2016-04-28 | Cortisol [Mass/volume] in Serum or Plasma | 12.6 | ug/dL | Morning sample, drawn before 9 a.m. | Normal | S |
| 2016-04-28 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 5 | {score} | S |
Vital signs recorded on 2016-04-28; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 71.8 kg; blood pressure 120/76, pulse 82 |
| Abdomen | Soft, non-tender; no mass |
| Extremities | No leg swelling; calf circumferences unchanged |
| Neurological | Pinprick slightly reduced over the toes; vibration sense and ankle reflexes present; strength normal; steady gait |
| Skin | Hair thinning; no rash |
| Psychiatric | Engaged and composed |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Postmenopausal bleeding for three weeks, about eight years after her last period, in a woman of 60 who takes no hormone therapy: endometrial cancer must be excluded. Office endometrial biopsy taken today, transvaginal ultrasound this week, and gynecologic oncology review booked | resolved | confirmed | N95.0 | S — Synthetic presenting problem; no symptom of her real illness was made public. Superseded by the diagnosis at the gynecologic oncology consultation. |
| Endometrioid adenocarcinoma of the endometrium, FIGO grade 2, mismatch repair deficient (loss of MLH1 and PMS2 staining), p53 wild-type pattern, on office endometrial biopsy, with enlarged right pelvic and para-aortic lymph nodes on CT; surgical staging planned; synthetic modern detail linked to her publicly reported endometrial cancer | active | confirmed | C54.1 | S — Synthetic histology, molecular result and extent; her family gave endometrial cancer as the cause of death (D), and nothing more about it was made public. |
| Metastatic endometrioid carcinoma in the right external iliac sentinel lymph node (9 mm deposit) and a left para-aortic lymph node (14 mm deposit), with the other nodes removed negative: FIGO 2013 stage IIIC2ii | active | confirmed | C77.8 | S — Synthetic nodal disease found at surgical staging. |
| Chemotherapy-induced peripheral neuropathy from paclitaxel: tingling in the toes, grade 1 (sensory only, no effect on daily activities) | active | confirmed | G62.0 | S — Synthetic common effect of paclitaxel. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Blood count with neutrophils and platelets | Before each chemotherapy cycle | Completed today | Hemoglobin 10.6 g/dL, white cells 4.3, neutrophils 2.1, platelets 196; cycle 4 can be given. Cycles 2 and 3 were given on schedule in the infusion center |
| Laboratory | Creatinine and estimated kidney function (carboplatin dose) | Before each cycle | Completed today | Creatinine 0.81 mg/dL, eGFR 83; carboplatin dose unchanged |
| Laboratory | Liver tests (paclitaxel and checkpoint inhibitor) | Baseline and before each checkpoint inhibitor dose | Completed today | ALT 24, AST 26 U/L, bilirubin 0.5 mg/dL |
| Laboratory | Magnesium | Before each cycle | Completed today | 1.8 mg/dL |
| Laboratory | TSH and free T4 (immune-related thyroid disease) | Baseline and before each checkpoint inhibitor dose | Completed today | TSH 4.8 mIU/L, just above range, with free T4 1.1 ng/dL: watch before each cycle |
| Laboratory | Glucose (immune-related diabetes) | Baseline and before each checkpoint inhibitor dose | Completed today | 97 mg/dL |
| Laboratory | Morning cortisol (immune-related adrenal and pituitary disease) | Baseline and before each checkpoint inhibitor dose | Deferred | 12.6 ug/dL today, normal. A deviation: the baseline cortisol deferred at cycle 1 was not drawn before cycles 2 and 3 either, because the request was not carried into the infusion center's standing orders. No harm resulted: today's value is normal and she has had no symptom of adrenal insufficiency. Corrective action: morning cortisol added to the standing orders before every remaining dose; no earlier values are recorded |
| Examination | Peripheral neuropathy: symptoms and examination | Baseline and before each taxane cycle | Completed today | Grade 1 sensory neuropathy; full dose continues |
| Examination | Lymphedema | Each visit after lymph node surgery | Completed today | No swelling; calf measurements unchanged |
| Examination | Immune-related adverse event symptoms (diarrhea, rash, cough, breathlessness, fatigue, headache) | Each visit on a checkpoint inhibitor | Completed today | None reported; skin and chest normal |
| Imaging | Response imaging | At the end of combination treatment, or sooner for symptoms | Not indicated | Not needed at the midpoint after complete resection, with no symptoms; CT after cycle 6 |
| Medication safety | Nausea and vomiting control | Each cycle | Completed today | Controlled: nausea one or two days per cycle, no vomiting |
| Medication safety | Paclitaxel infusion reaction prevention | Each paclitaxel dose | Completed today | No reaction in three cycles; same premedication |
| Survey | Distress and depression screen (PHQ-9) | At diagnosis, each treatment phase, and when symptoms change | Completed today | PHQ-9 5 |
Goal progress:
Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Uterine Neoplasms (2026); Mirza MR, et al. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer (RUBY). N Engl J Med 2023;388(23):2145-2158 (PMID 36972026) (2023); JEMPERLI (dostarlimab-gxly) injection, prescribing information (2026); Salani R, et al. Updates to post-treatment surveillance after curative intent treatment for patients with gynecologic cancers: A Society of Gynecologic Oncology clinical practice statement. Gynecol Oncol 2026;204:109-117 (PMID 41308226) (2026); Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 2021;39(36):4073-4126 (PMID 34724392) (2021); Hesketh PJ, et al. Antiemetics: ASCO Guideline Update. J Clin Oncol 2020;38(24):2782-2797 (2020); Loprinzi CL, et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol 2020;38(28):3325-3348 (2020); CMID: Clinical Monitoring Intelligence Database, endometrial cancer and hypothyroidism monographs (2026); Depression and Suicide Risk in Adults: Screening (2023)
Follow-up: Cycles 5 and 6 every 21 days, with TSH, free T4 and a morning cortisol before each. CT about two weeks after cycle 6, then a review with the result and the first maintenance dose. Next scheduled visit 2016-06-30: end of combination treatment: response CT, immune-related hypothyroidism, the first maintenance dostarlimab dose, and the survivorship plan. [S]